CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company’s shares closed yesterday ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.10 or -7.94% from the prior close of $1.26. The stock opened at $1.24 and touched a low of $1 ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.31 which represents a slight increase of $0.04 or 3.15% from the prior close of $1.27. The stock opened at $1.27 and touched ...

Fintel reports that on December 13, 2024, Chardan Capital downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Buy to Neutral. Analyst Price Forecast Suggests 347.16% Upside As of ...

Editas Medicine extends its cash runway to Q2 2027 while prioritizing in vivo gene editing programs. JPMorgan downgrades Editas to Underweight, citing unclear timelines and limited near-term ...